Aileron Presents Proof-of-Concept Clinical Data for ALRN-6924 in Late-Breaking Presentation at EORTC-NCI-AACR Symposium

Transforming the Experience of Chemotherapy for Patients

What's New at Aileron

Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.

ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.

Latest News